Autolus Therapeutics (AUTL) Competitors $1.33 +0.04 (+3.10%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.33 0.00 (0.00%) As of 05/16/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. VERA, DYN, GPCR, ANIP, SPRY, CALT, ETNB, OCUL, AMPH, and BGMShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Ocular Therapeutix (OCUL), Amphastar Pharmaceuticals (AMPH), and Qilian International Holding Group (BGM). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Vera Therapeutics Dyne Therapeutics Structure Therapeutics ANI Pharmaceuticals ARS Pharmaceuticals Calliditas Therapeutics AB (publ) 89bio Ocular Therapeutix Amphastar Pharmaceuticals Qilian International Holding Group Vera Therapeutics (NASDAQ:VERA) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends. Does the MarketBeat Community prefer VERA or AUTL? Autolus Therapeutics received 187 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 68.25% of users gave Autolus Therapeutics an outperform vote while only 66.15% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes4366.15% Underperform Votes2233.85% Autolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% Which has more risk and volatility, VERA or AUTL? Vera Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Do institutionals and insiders hold more shares of VERA or AUTL? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, VERA or AUTL? Vera Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$3.00-7.08Autolus Therapeutics$9.01M39.28-$208.38M-$0.88-1.51 Do analysts recommend VERA or AUTL? Vera Therapeutics presently has a consensus target price of $63.33, suggesting a potential upside of 198.04%. Autolus Therapeutics has a consensus target price of $9.32, suggesting a potential upside of 600.75%. Given Autolus Therapeutics' higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VERA or AUTL more profitable? Vera Therapeutics' return on equity of -50.13% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% Autolus Therapeutics N/A -63.65%-36.54% Does the media prefer VERA or AUTL? In the previous week, Vera Therapeutics had 12 more articles in the media than Autolus Therapeutics. MarketBeat recorded 17 mentions for Vera Therapeutics and 5 mentions for Autolus Therapeutics. Vera Therapeutics' average media sentiment score of 0.66 beat Autolus Therapeutics' score of 0.55 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAutolus Therapeutics beats Vera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$353.97M$2.88B$5.36B$8.52BDividend YieldN/A1.72%4.94%4.11%P/E Ratio-1.1031.3127.0420.05Price / Sales39.28408.24390.47119.71Price / CashN/A168.6838.2534.62Price / Book2.083.066.764.60Net Income-$208.38M-$72.35M$3.23B$248.70M7 Day Performance0.76%3.92%4.83%5.15%1 Month Performance-6.99%8.36%9.88%14.04%1 Year Performance-69.70%-28.65%15.35%6.76% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics3.0145 of 5 stars$1.33+3.1%$9.32+600.8%-69.7%$353.97M$9.01M-1.10330VERAVera Therapeutics3.4297 of 5 stars$22.49+3.6%$63.33+181.6%-48.7%$1.43BN/A-8.6240News CoverageAnalyst RevisionGap UpDYNDyne Therapeutics3.6052 of 5 stars$12.56+10.1%$46.85+273.0%-57.3%$1.43BN/A-3.53100News CoverageGap UpHigh Trading VolumeGPCRStructure Therapeutics2.1306 of 5 stars$24.62-3.7%$78.00+216.8%-30.4%$1.41BN/A-33.27136Analyst RevisionANIPANI Pharmaceuticals4.8501 of 5 stars$62.30-6.0%$80.13+28.6%-2.3%$1.36B$614.38M-113.27600News CoverageEarnings ReportInsider TradeHigh Trading VolumeSPRYARS Pharmaceuticals3.2369 of 5 stars$13.29-1.1%$31.00+133.3%+50.6%$1.31B$89.15M-26.0690News CoveragePositive NewsEarnings ReportAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180ETNB89bio3.0148 of 5 stars$8.11+5.3%$27.25+236.0%-9.8%$1.18BN/A-2.7940Positive NewsGap UpOCULOcular Therapeutix4.2174 of 5 stars$7.39+4.7%$16.25+119.9%+17.0%$1.18B$59.65M-5.60230News CoverageGap UpAMPHAmphastar Pharmaceuticals4.1693 of 5 stars$24.34+1.0%$32.33+32.8%-42.8%$1.16B$731.97M8.111,620BGMQilian International Holding GroupN/A$11.42+3.5%N/AN/A$1.11B$25.10M0.00298Positive NewsGap Up Related Companies and Tools Related Companies Vera Therapeutics Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors ANI Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors 89bio Competitors Ocular Therapeutix Competitors Amphastar Pharmaceuticals Competitors Qilian International Holding Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 5/18/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Two drop-dead simple ways to play the gold boomIf you take a few minutes to check out the short research briefing Mark & I have put together, I’m confident y...Eagle Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts